Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

TEVA PHARMACEUTICAL INDUSTRIES LTD : Change in Directors or Principal Officers (form 8-K)

11/24/2021 | 07:53am EST

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) Departure of Andrew Weil, Chief Accounting Officer

Andrew Weil, Teva's Chief Accounting Officer, will step down from his role as Chief Accounting Officer, effective November 24, 2021.

(c) Appointment of Amir Weiss as Chief Accounting Officer

Amir Weiss, currently Vice President of Finance and Corporate Controller, was promoted to Senior Vice President and Chief Accounting Officer, effective November 24, 2021.

Mr. Weiss, 44, joined Teva in June 2012 and has served in several senior finance-related positions, including Vice President Corporate Finance (October 2019 - November 2021) and VP Finance, International Markets (April 2014 - October 2019). Prior to joining Teva, Mr. Weiss served as Corporate Controller at RADCOM Ltd. from 2008 to 2012. From 2006 to 2008, he served as Corporate Controller at Oblicore Inc. Mr. Weiss holds an MA in law, an MBA and a Bachelor's degree in Economics and Accounting from Bar Ilan University. Mr. Weiss is a Certified Public Accountant.

In connection with his promotion to Senior Vice President and Chief Accounting Officer, Mr. Weiss's terms of employment were modified to increase his initial base salary to 840,000 New Israeli Shekels, with eligibility to be considered for an annual cash incentive with a target amount equal to 50% of his annual base salary and for equity-based awards under the Company's equity compensation plan.

Mr. Weiss does not have any family relationships with any of the Company's directors or executive officers and is not party to any transactions required to be disclosed under Item 404(a) of Regulation S-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
01/18Teva settles shareholder lawsuit over generic drug pricing for $420 mln
RE
01/18Teva settles shareholder lawsuit over generic drug pricing for $420 mln
RE
01/18Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Res..
BU
01/18IMMUNEERING CORP : Change in Directors or Principal Officers, Financial Statements and Exh..
AQ
01/18Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M...
AQ
01/06Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Mo..
AQ
01/04Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
BU
01/03Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President,áProject and Allian..
AQ
2021Thinking about buying stock in SuperCom, Teva Pharmaceutical, Future Fintech Group, Spr..
PR
2021ADRs End Mostly Higher; Teva Down on Opioid Verdict
DJ
More news
Analyst Recommendations on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
More recommendations
Financials (USD)
Sales 2021 16 194 M - -
Net income 2021 954 M - -
Net Debt 2021 21 746 M - -
P/E ratio 2021 11,6x
Yield 2021 -
Capitalization 9 530 M 9 530 M -
EV / Sales 2021 1,93x
EV / Sales 2022 1,79x
Nbr of Employees 37 736
Free-Float -
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 8,84 $
Average target price 10,47 $
Spread / Average Target 18,5%
EPS Revisions
Managers and Directors
Kňre Schultz President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Hafrun Fridriksdottir President-Global Generics Research & Development
Eric DrapÚ Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED10.36%9 751
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
ABBVIE INC.-0.14%239 035
NOVO NORDISK A/S-12.67%223 059